Yarrow Bioscience (NASDAQ:YARW) Posts Earnings Results

Yarrow Bioscience (NASDAQ:YARW) announced its earnings results on Thursday. The company reported ($2.14) EPS for the quarter, Zacks reports. Yarrow Bioscience had a negative net margin of 4,726.21% and a negative return on equity of 70.42%.

Yarrow Bioscience Trading Down 0.6%

Yarrow Bioscience stock traded down $0.28 during midday trading on Friday, hitting $42.45. 3,938 shares of the stock were exchanged, compared to its average volume of 11,430. Yarrow Bioscience has a fifty-two week low of $14.02 and a fifty-two week high of $46.95. The stock has a market cap of $28.44 million, a P/E ratio of -2.23 and a beta of 1.96.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. TD Cowen assumed coverage on Yarrow Bioscience in a research note on Tuesday, July 28th. They issued a “buy” rating on the stock. BTIG Research started coverage on Yarrow Bioscience in a research note on Monday, August 3rd. They issued a “buy” rating and a $58.00 price objective for the company. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Yarrow Bioscience presently has a consensus rating of “Buy” and an average price target of $58.00.

About Yarrow Bioscience

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.